Teodora Djikic-Stojsic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Teodora Djikic-Stojsic has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Katarina Nikolic
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia
2 shared publications - Milan Jovanović
Faculty of Pharmacy, University of Belgrade
2 shared publications - Branislav Stanković
Department of Nuclear and Plasma Physics, “VINCA” Institute of Nuclear Sciences—National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12–14, Vinca, 11351 Belgrade, Serbia
1 shared publication - Marija Popović-Nikolić
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia
1 shared publication
Latest Publications
- Open Access
A Computational Framework for the Design and Development of Isoform Selective PI3Kα Inhibitors as Novel Anticancer Agents
Background: Phosphatidylinositol 3-kinase (PI3K) is a promising anticancer drug target, and selective PI3Kα inhibition may provide both efficacy and an improved safety profile. This study aimed to design new potentially selective PI3Kα inhibitors using computer-aided drug design (CADD). Methods: Benzoxazepine and thiazole derivatives were investigated using molecular dynamics, ensemble docking, and Three-Dimensional Quantitative Structure–Activity Relationship (3D-QSAR) analyses. Scaffold hopping, substituent replacement, structure-based virtual screening, and density functional theory (DFT) calculations were then applied to guide the design and characterization of new derivatives. Results: The study identified new chemotypes capable of interacting with PI3Kα Val851 (αVal851) in the hinge region, including chromeno[3,4-d]imidazole, 2H-benzo[b]oxazine, and quinoline derivatives. Additional substructures directed toward hydrophobic region II and the αGln859 interaction environment supported predicted selectivity over PI3Kβ, PI3Kγ, and PI3Kδ. Conclusions: The results establish a comprehensive CADD framework for the rational design of selective PI3Kα inhibitors and provide new compounds with improved predicted selectivity profiles for further development.
Open AccessA Computational Framework for the Design and Development of Isoform Selective PI3Kα Inhibitors as Novel Anticancer Agents
Background: Phosphatidylinositol 3-kinase (PI3K) is a promising anticancer drug target, and selective PI3Kα inhibition may provide both efficacy and an improved safety profile. This study aimed to design new potentially selective PI3Kα inhibitors using computer-aided drug design (CADD). Methods: Benzoxazepine and thiazole derivatives were investigated using molecular dynamics, ensemble docking, and Three-Dimensional Quantitative Structure–Activity Relationship (3D-QSAR) analyses. Scaffold hopping, substituent replacement, structure-based virtual screening, and density functional theory (DFT) calculations were then applied to guide the design and characterization of new derivatives. Results: The study identified new chemotypes capable of interacting with PI3Kα Val851 (αVal851) in the hinge region, including chromeno[3,4-d]imidazole, 2H-benzo[b]oxazine, and quinoline derivatives. Additional substructures directed toward hydrophobic region II and the αGln859 interaction environment supported predicted selectivity over PI3Kβ, PI3Kγ, and PI3Kδ. Conclusions: The results establish a comprehensive CADD framework for the rational design of selective PI3Kα inhibitors and provide new compounds with improved predicted selectivity profiles for further development.
- Open Access
- 1 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
A Computational Framework for the Design and Development of Isoform Selective PI3Kα inhibitors as Novel Anticancer Agents
Phosphatidylinositol 3-kinase (PI3K) has emerged as a promising target for the development of new anticancer drugs. Selective inhibition of the PI3Kα isoform is considered a favourable strategy, providing not only the required efficacy but also a potentially improved safety profile. Modern CADD (Computer Aided Drug Design) methodologies, incorporating both ligand-based and structure-based approaches, offer valuable guidance for the design of novel PI3Kα inhibitors. Benzoxazepine and thiazole derivatives were investigated through a combination of molecular dynamics, ensemble docking, and 3D-QSAR (Three-Dimensional Quantitative Structure–Activity Relationship) studies to identify structural features critical for PI3Kα activity and selectivity over PI3Kβ, PI3Kγ, and PI3Kδ. Subsequently, scaffold-hopping and R-group replacement were applied to design structurally diverse, potentially selective PI3Kα inhibitors with these defined characteristics. A structure-based virtual screening protocol was also implemented to identify new moieties with selective PI3Kα inhibitory potential. The study defined new chemotypes capable of binding to αVal851 in the hinge region, crucial for PI3Kα inhibition, including chromeno[3,4-d]imidazole, 2H-benzo[b][1,4]oxazine, and quinoline derivatives. Additional substructures binding to the hydrophobic region, particularly αGln859, contributed to isoform selectivity as shown by 3D-QSAR predictions. Compounds identified by virtual screening also displayed interactions with the hinge region and non-conserved amino acids, further supporting selective PI3Kα inhibition. Overall, this study establishes a comprehensive CADD framework and presents a series of rationally designed PI3Kα inhibitors with improved predicted selectivity profiles, providing a foundation for the future development of targeted therapies.
- 1 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA Computational Framework for the Design and Development of Isoform Selective PI3Kα inhibitors as Novel Anticancer Agents
Phosphatidylinositol 3-kinase (PI3K) has emerged as a promising target for the development of new anticancer drugs. Selective inhibition of the PI3Kα isoform is considered a favourable strategy, providing not only the required efficacy but also a potentially improved safety profile. Modern CADD (Computer Aided Drug Design) methodologies, incorporating both ligand-based and structure-based approaches, offer valuable guidance for the design of novel PI3Kα inhibitors. Benzoxazepine and thiazole derivatives were investigated through a combination of molecular dynamics, ensemble docking, and 3D-QSAR (Three-Dimensional Quantitative Structure–Activity Relationship) studies to identify structural features critical for PI3Kα activity and selectivity over PI3Kβ, PI3Kγ, and PI3Kδ. Subsequently, scaffold-hopping and R-group replacement were applied to design structurally diverse, potentially selective PI3Kα inhibitors with these defined characteristics. A structure-based virtual screening protocol was also implemented to identify new moieties with selective PI3Kα inhibitory potential. The study defined new chemotypes capable of binding to αVal851 in the hinge region, crucial for PI3Kα inhibition, including chromeno[3,4-d]imidazole, 2H-benzo[b][1,4]oxazine, and quinoline derivatives. Additional substructures binding to the hydrophobic region, particularly αGln859, contributed to isoform selectivity as shown by 3D-QSAR predictions. Compounds identified by virtual screening also displayed interactions with the hinge region and non-conserved amino acids, further supporting selective PI3Kα inhibition. Overall, this study establishes a comprehensive CADD framework and presents a series of rationally designed PI3Kα inhibitors with improved predicted selectivity profiles, providing a foundation for the future development of targeted therapies.